Guidance for Industry on Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation; Availability, 15956-15957 [2013-05725]

Download as PDF 15956 Federal Register / Vol. 78, No. 49 / Wednesday, March 13, 2013 / Notices sponsor may disagree with one of these decisions, and a dispute arises. Because these disputes often involve complex scientific or procedural matters and also may be precedent setting, it is critical that there be procedures in place to encourage open, prompt discussion of such disputes. The procedures and policies described in this guidance are intended to promote rapid resolution of scientific and procedural disputes between sponsors and FDA. This draft guidance is a revision of the guidance of the same name that published in February 2000. The procedures and policies have been updated to reflect the current practices. This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the Agency’s current thinking on formal dispute resolution regarding appeals above the division level. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. mstockstill on DSK4VPTVN1PROD with NOTICES II. The Paperwork Reduction Act of 1995 This draft guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collections of information in this draft guidance have been approved under OMB control number 0910–0430. This draft guidance is a revision of an earlier version of the guidance. The revised version contains no additional information collections; therefore, it continues to be covered under OMB control number 0910–0430. III. Comments Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http:// www.regulations.gov. IV. Electronic Access Persons with access to the Internet may obtain the document at http:// VerDate Mar<15>2010 17:11 Mar 12, 2013 Jkt 229001 www.fda.gov/Drugs/ GuidanceCompliance RegulatoryInformation/Guidances/ default.htm, http://www.fda.gov/ BiologicsBloodVaccines/Guidance ComplianceRegulatoryInformation/ default.htm, or http:// www.regulations.gov. Food and Drug Administration assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. Submit electronic comments on the guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA– 305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Russell Wesdyk, Center for Drug Evaluation and Research (HFD–003), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 4182, Silver Spring, MD 20993–0002, 301–796–2400. SUPPLEMENTARY INFORMATION: [Docket No. FDA–2011–D–0595] I. Background Guidance for Industry on Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation; Availability FDA is announcing the availability of a guidance for industry entitled ‘‘Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation.’’ This guidance provides recommendations to sponsors of NDAs and ANDAs regarding what criteria should be met when evaluating and labeling tablets that have been scored. (A scoring feature facilitates tablet splitting, which is the practice of breaking or cutting a higher-strength tablet into smaller portions.) Specifically, this guidance recommends: • Guidelines to follow, data to provide, and criteria to meet and detail in an application to support approval of a scored tablet; and • Nomenclature and labeling for approved scored tablets. On August 30, 2011 (76 FR 53909), FDA announced the availability of the draft version of this guidance. The public comment period closed on November 28, 2011. A number of comments were received from the public, all of which the Agency considered carefully as it finalized the guidance and made appropriate changes. The Agency also held an Advisory Committee for Pharmaceutical Science and Clinical Pharmacology meeting on August 9, 2012, to discuss the draft guidance. Any changes to the guidance were minor and made to clarify statements in the draft guidance. The Agency has previously considered tablet scoring as an issue when determining whether a generic drug product is the same as the reference listed drug (RLD). One characteristic of a tablet dosage form is that it may be manufactured with a score or scores. This characteristic is useful because the score can be used to facilitate the splitting of the tablet into fractions when less than a full tablet is desired for a dose. Although there are Dated: March 7, 2013. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2013–05721 Filed 3–12–13; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ‘‘Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation.’’ This guidance provides recommendations to sponsors of new drug applications (NDAs) and abbreviated new drug applications (ANDAs) regarding what criteria should be met when evaluating and labeling tablets that have been scored. (A scoring feature facilitates tablet splitting, which is the practice of breaking or cutting a higher-strength tablet into smaller portions.) Specifically, this guidance recommends guidelines to follow, data to provide, and criteria to meet and detail in an application to support approval of a scored tablet; and nomenclature and labeling for approved scored tablets. This guidance does not address specific finished-product release testing, where additional requirements may apply to scored tablets. This guidance does not describe the medical practice conditions under which tablet splitting is considered or recommended. DATES: Submit either electronic or written comments on Agency guidances at any time. ADDRESSES: Submit written requests for single copies of this guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 2201, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to SUMMARY: PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 E:\FR\FM\13MRN1.SGM 13MRN1 mstockstill on DSK4VPTVN1PROD with NOTICES Federal Register / Vol. 78, No. 49 / Wednesday, March 13, 2013 / Notices no standards or regulatory requirements that specifically address scoring of tablets, the Agency recognizes the need for consistent scoring between a generic product and its RLD. Consistent scoring ensures that the patient is able to adjust the dose, by splitting the tablet, in the same manner as the RLD. This enables the patient to switch between products made by different manufacturers without encountering problems related to the dose. In addition, consistent scoring ensures that neither the generic product nor the RLD has an advantage in the marketplace because one is scored and one is not. The Center for Drug Evaluation and Research’s Drug Safety Oversight Board considered the practice of tablet splitting at its October 2009 and November 2010 meetings. During those meetings, they discussed how insurance companies and doctors are increasingly recommending that patients split tablets, either to adjust the patients’ dose or as a cost-saving measure. Because of this, the Agency conducted internal research on tablet splitting and concluded that in some cases, there are possible safety issues, especially when tablets are not scored or evaluated for splitting. The Agency’s concerns with splitting a tablet included variations in the tablet content, weight, disintegration, or dissolution, which can affect how much drug is present in a split tablet and available for absorption. In addition, there may be stability issues with splitting tablets. Tablet splitting also is addressed in pharmacopeial standards. The European Pharmacopeia currently applies accuracy of subdivision standards for scored tablets—and has at various times also included standards for content uniformity, weight variation, and loss of mass—while the United States Pharmacopeia published a Stimuli article in 2009 proposing criteria for loss of mass and accuracy of subdivision for split tablets. As an outgrowth of these discussions, FDA is providing recommendations for application content regarding the scientific basis for functional scoring on solid oral dosage form products to ensure the quality of both NDA and ANDA scored tablet products. To accomplish this, the Agency has developed consistent and meaningful criteria by which scored tablets can be evaluated and labeled by: (1) Providing a harmonized approach to chemistry, VerDate Mar<15>2010 17:11 Mar 12, 2013 Jkt 229001 manufacturing, and controls reviews of scored tablets; (2) ensuring consistency in nomenclature (e.g., score versus bisect) and labeling; and (3) providing information through product labeling or other means to health care providers. This guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The guidance represents the Agency’s current thinking on tablet scoring: Nomenclature, labeling, and data for evaluation. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. II. Comments Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http:// www.regulations.gov. III. The Paperwork Reduction Act of 1995 This guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501– 3520). The collections of information in § 201.57 (21 CFR 201.57) and 21 CFR 314.50 and 314.70 have been approved under OMB control numbers 0910–0572 (for § 201.57) and 0910–0001 (for 21 CFR part 314). IV. Electronic Access Persons with access to the Internet may obtain the document at either http://www.fda.gov/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/default.htm or http:// www.regulations.gov. Dated: March 7, 2013. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2013–05725 Filed 3–12–13; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2013–N–0001] Food and Drug Administration/Xavier University Global Medical Device Conference AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public conference. The Food and Drug Administration (FDA) Cincinnati District, in cosponsorship with Xavier University, is announcing a public conference entitled ‘‘FDA/Xavier University Global Medical Device Conference.’’ This 3-day public conference includes presentations from key FDA officials and industry experts with small group breakout sessions. The conference is intended for companies of all sizes and employees at all levels. Date and Time: The public conference will be held on May 1, 2013, from 8:30 a.m. to 5 p.m.; May 2, 2013, from 8:30 a.m. to 5 p.m.; and May 3, 2013, from 8:30 a.m. to 1 p.m. Location: The public conference will be held on the campus of Xavier University, 3800 Victory Pkwy., Cincinnati, OH 45207, 513–745–3073 or 513–745–3396. Contact Persons: For information regarding this notice: Gina Brackett, Food and Drug Administration, 6751 Steger Dr., Cincinnati, OH 45237, 513– 679–2700, Fax: 513–679–2771, Gina.Brackett@fda.hhs.gov. For information regarding the conference and registration: Marla Phillips, Xavier University, 3800 Victory Pkwy., Cincinnati, OH 45207, 513–745–3073, phillipsm4@xavier.edu. Registration: There is a registration fee. The conference registration fees cover the cost of the presentations, training materials, receptions, breakfasts, and lunches for the 3 days of the conference. Early registration ends March 13, 2013. Standard registration ends April 9, 2013. There will be onsite registration. The cost of registration is as follows: SUMMARY: BILLING CODE 4160–01–P PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 15957 E:\FR\FM\13MRN1.SGM 13MRN1

Agencies

[Federal Register Volume 78, Number 49 (Wednesday, March 13, 2013)]
[Notices]
[Pages 15956-15957]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-05725]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-D-0595]


Guidance for Industry on Tablet Scoring: Nomenclature, Labeling, 
and Data for Evaluation; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
availability of a guidance for industry entitled ``Tablet Scoring: 
Nomenclature, Labeling, and Data for Evaluation.'' This guidance 
provides recommendations to sponsors of new drug applications (NDAs) 
and abbreviated new drug applications (ANDAs) regarding what criteria 
should be met when evaluating and labeling tablets that have been 
scored. (A scoring feature facilitates tablet splitting, which is the 
practice of breaking or cutting a higher-strength tablet into smaller 
portions.) Specifically, this guidance recommends guidelines to follow, 
data to provide, and criteria to meet and detail in an application to 
support approval of a scored tablet; and nomenclature and labeling for 
approved scored tablets.
    This guidance does not address specific finished-product release 
testing, where additional requirements may apply to scored tablets. 
This guidance does not describe the medical practice conditions under 
which tablet splitting is considered or recommended.

DATES: Submit either electronic or written comments on Agency guidances 
at any time.

ADDRESSES: Submit written requests for single copies of this guidance 
to the Division of Drug Information, Center for Drug Evaluation and 
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 
51, Rm. 2201, Silver Spring, MD 20993-0002. Send one self-addressed 
adhesive label to assist that office in processing your requests. See 
the SUPPLEMENTARY INFORMATION section for electronic access to the 
guidance document.
    Submit electronic comments on the guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets 
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Russell Wesdyk, Center for Drug 
Evaluation and Research (HFD-003), Food and Drug Administration, 10903 
New Hampshire Ave., Bldg. 51, Rm. 4182, Silver Spring, MD 20993-0002, 
301-796-2400.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a guidance for industry 
entitled ``Tablet Scoring: Nomenclature, Labeling, and Data for 
Evaluation.'' This guidance provides recommendations to sponsors of 
NDAs and ANDAs regarding what criteria should be met when evaluating 
and labeling tablets that have been scored. (A scoring feature 
facilitates tablet splitting, which is the practice of breaking or 
cutting a higher-strength tablet into smaller portions.) Specifically, 
this guidance recommends:
     Guidelines to follow, data to provide, and criteria to 
meet and detail in an application to support approval of a scored 
tablet; and
     Nomenclature and labeling for approved scored tablets.
    On August 30, 2011 (76 FR 53909), FDA announced the availability of 
the draft version of this guidance. The public comment period closed on 
November 28, 2011. A number of comments were received from the public, 
all of which the Agency considered carefully as it finalized the 
guidance and made appropriate changes. The Agency also held an Advisory 
Committee for Pharmaceutical Science and Clinical Pharmacology meeting 
on August 9, 2012, to discuss the draft guidance. Any changes to the 
guidance were minor and made to clarify statements in the draft 
guidance.
    The Agency has previously considered tablet scoring as an issue 
when determining whether a generic drug product is the same as the 
reference listed drug (RLD). One characteristic of a tablet dosage form 
is that it may be manufactured with a score or scores. This 
characteristic is useful because the score can be used to facilitate 
the splitting of the tablet into fractions when less than a full tablet 
is desired for a dose. Although there are

[[Page 15957]]

no standards or regulatory requirements that specifically address 
scoring of tablets, the Agency recognizes the need for consistent 
scoring between a generic product and its RLD.
    Consistent scoring ensures that the patient is able to adjust the 
dose, by splitting the tablet, in the same manner as the RLD. This 
enables the patient to switch between products made by different 
manufacturers without encountering problems related to the dose. In 
addition, consistent scoring ensures that neither the generic product 
nor the RLD has an advantage in the marketplace because one is scored 
and one is not.
    The Center for Drug Evaluation and Research's Drug Safety Oversight 
Board considered the practice of tablet splitting at its October 2009 
and November 2010 meetings. During those meetings, they discussed how 
insurance companies and doctors are increasingly recommending that 
patients split tablets, either to adjust the patients' dose or as a 
cost-saving measure. Because of this, the Agency conducted internal 
research on tablet splitting and concluded that in some cases, there 
are possible safety issues, especially when tablets are not scored or 
evaluated for splitting. The Agency's concerns with splitting a tablet 
included variations in the tablet content, weight, disintegration, or 
dissolution, which can affect how much drug is present in a split 
tablet and available for absorption. In addition, there may be 
stability issues with splitting tablets.
    Tablet splitting also is addressed in pharmacopeial standards. The 
European Pharmacopeia currently applies accuracy of subdivision 
standards for scored tablets--and has at various times also included 
standards for content uniformity, weight variation, and loss of mass--
while the United States Pharmacopeia published a Stimuli article in 
2009 proposing criteria for loss of mass and accuracy of subdivision 
for split tablets.
    As an outgrowth of these discussions, FDA is providing 
recommendations for application content regarding the scientific basis 
for functional scoring on solid oral dosage form products to ensure the 
quality of both NDA and ANDA scored tablet products. To accomplish 
this, the Agency has developed consistent and meaningful criteria by 
which scored tablets can be evaluated and labeled by: (1) Providing a 
harmonized approach to chemistry, manufacturing, and controls reviews 
of scored tablets; (2) ensuring consistency in nomenclature (e.g., 
score versus bisect) and labeling; and (3) providing information 
through product labeling or other means to health care providers.
    This guidance is being issued consistent with FDA's good guidance 
practices regulation (21 CFR 10.115). The guidance represents the 
Agency's current thinking on tablet scoring: Nomenclature, labeling, 
and data for evaluation. It does not create or confer any rights for or 
on any person and does not operate to bind FDA or the public. An 
alternative approach may be used if such approach satisfies the 
requirements of the applicable statutes and regulations.

II. Comments

    Interested persons may submit either electronic comments regarding 
this document to http://www.regulations.gov or written comments to the 
Division of Dockets Management (see ADDRESSES). It is only necessary to 
send one set of comments. Identify comments with the docket number 
found in brackets in the heading of this document. Received comments 
may be seen in the Division of Dockets Management between 9 a.m. and 4 
p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.

III. The Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of 
information found in FDA regulations. These collections of information 
are subject to review by the Office of Management and Budget (OMB) 
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The 
collections of information in Sec.  201.57 (21 CFR 201.57) and 21 CFR 
314.50 and 314.70 have been approved under OMB control numbers 0910-
0572 (for Sec.  201.57) and 0910-0001 (for 21 CFR part 314).

IV. Electronic Access

    Persons with access to the Internet may obtain the document at 
either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov.

    Dated: March 7, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-05725 Filed 3-12-13; 8:45 am]
BILLING CODE 4160-01-P